grants_govPAR-27-026
Open
Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
- Response deadline
- Sep 25, 2028 Due in 708 days
- Date posted
- Jun 9, 2026
- Source
- Open notice
Description
The purpose of this notice of funding opportunity (NOFO) is to support innovative basic, clinical, translational, and implementation science research relevant to HIV and substance use. This initiative encourages high risk high impact transformative studies that advance knowledge and strategies for HIV prevention, diagnosis, treatment and virus suppression in people who use substances and/or have a substance use disorder.
Classifications
- NAICS93.279
Documents (1)
- DownloadPAR-27-026-Full-Announcement.htmltext/html;charset=UTF-8135 KB
Contacts
Similar contracts
- Neural Ensembles & Used Substances (NExUS) Collaboratory: Building a Multimodal Inventory of Cell Ensembles Encoding the Effects of Addictive Substances (U01 Clinical Trial Not Allowed)Due Feb 8, 2027
- Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)Due Jun 16, 2028
- BRAIN Initiative: Integrative Team-Research BRAIN Circuits Program - iBCP (RM1 Clinical Trial Not Allowed)Due Jun 23, 2028
- Limited Competition: Growing Great Ideas: Research Education Course in Entrepreneurship and Product Development for Researchers Studying Drug Use, Drug Misuse, and Drug Addiction (UE5 Clinical Trial Not Allowed)Due Oct 1, 2026
- Science Track Award for Research Transition (START) Program (R03, Clinical Trial Optional)Due Mar 16, 2029
- HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)Due Feb 9, 2029